Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients

NCT03181932 is registered in ClinicalTrials.gov with Savara Inc. as lead sponsor.

NCT NCT03181932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Lead sponsor
Savara Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 20, 2017
Completion date
January 15, 2021
Enrollment
188 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, mrsa